138 related articles for article (PubMed ID: 23194040)
1. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer biomarkers: present status and future developments.
Cagle PT; Allen TC; Olsen RJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
4. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
6. Advances in treatment of lung cancer with targeted therapy.
Cagle PT; Chirieac LR
Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
[TBL] [Abstract][Full Text] [Related]
7. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
9. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
10. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
Kulesza P; Ramchandran K; Patel JD
Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
[TBL] [Abstract][Full Text] [Related]
11. [Lung cancer].
Ayabe E; Kaira K; Yamamoto N
Gan To Kagaku Ryoho; 2009 Jan; 36(1):21-5. PubMed ID: 19151561
[TBL] [Abstract][Full Text] [Related]
12. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment.
Sudhindra A; Ochoa R; Santos ES
Clin Lung Cancer; 2011 Nov; 12(6):360-8. PubMed ID: 21729648
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
15. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
16. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
17. Personalized therapy of lung cancer.
Thomas R; Wolf J
Onkologie; 2012; 35 Suppl 1():14-9. PubMed ID: 22286583
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
